BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Ajanta Pharma Ltd.’s Q1 missed our estimates by 5%/15% on top-line and profit after tax (adjusted for forex gain of Rs 250 million).
Ebitda margins at 29.4% contracted 480 basis points QoQ despite 77% gross margins as cost structures normalised in Q1.
Revenue grew 13% YoY, driven by strong recovery in India (32% YoY).
Field force rationalisation aided in productivity.
Exports performance was muted at 6% YoY growth with U.S. steady at $23 million (lack of major launch), branded business up 8% YoY.
Tender business declined owing to its lumpy nature.
Ajanta Pharma's management remained confident of outperforming market growth of its major geographies (India, Asia and Africa) and maintaining Ebitda margins at 29-30% for FY22E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR